$NGM News
Last published 1y ago
- 1y agoNGMXaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating OfficerBusiness WireXaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development Jeff Jonker, a biotech industry veteran and former CEO of
- 2y agoNGMNGM Bio Announces Closing of Tender OfferGlobeNewswireSAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today
- 2y agoCTLTHRTNGMSDPIKuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law FirmGlobeNewswireNEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoNGMNGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for
- 2y agoNGMNGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA®
- 2y agoAAAGTIGLTNGMKuehn Law Encourages AGTI, GLT, NGM, and AA Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoNGMNGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPGlobeNewswireNGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in
- 2y agoNGMNGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today
- 2y agoNGMNGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet NeedGlobeNewswireEncouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody, in
- 2y agoNGMNGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®GlobeNewswire--As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of
- 3y agoNGMNGM Bio to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for
- 3y agoNGMNGM Bio Reports Third Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewswire--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438-- --Selected for an
- 3y agoNGMNGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for
- 3y agoARENGMAlexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel MedicinesPR NewswireAlexandria is well positioned to support companies in the growing area of AI-enhanced laboratory-based research and development, which is contributing to demand for advanced laboratory infrastructure
- 3y agoNGMNGM Bio to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients,
- 3y agoNGMNGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023GlobeNewswireAldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid synthesis) and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-DAround 25-50% of patients with
- 3y agoNGMNGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 DataGlobeNewswirePhase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due
- 3y agoNGMNGM Bio to Participate in the Cowen 43rd Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for
- 3y agoNGMNGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswire--Presented preliminary findings from the Phase 1a monotherapy dose escalation portion of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the ESMO I-O Annual Congress--
- 3y agoNGMNGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for
- 3y agoNGMNGM Bio Outlines Corporate Strategy and Provides Guidance on Key PrioritiesGlobeNewswireNGM Bio's three-pronged corporate strategy includes the following components: Focus internal clinical development efforts on solid tumor oncology portfolioGenerate next-generation biologics through prolific in-house
- 3y agoNGMBelharra Therapeutics Debuts With $130 Million in FundingBusiness Wire--Next-generation chemoproteomics company launched by Versant Ventures' Inception Discovery Engine with ability to target any binding site, on any protein, in any cell type-- --Emerges from stealth with a $50 million
- 3y agoNGMNGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual MeetingGlobeNewswire--NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical in vivo and in
- 3y agoNGMNGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual MeetingGlobeNewswireNGM707 was generally well tolerated to the highest dose evaluated (1800 mg) in the monotherapy escalation; maximum tolerated dose was not reachedLinear pharmacokinetics (PK) was observed at doses ≥200 mg, and analysis of
- 4y agoNGMNGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual MeetingGlobeNewswirePoster presentation to showcase initial data from the Phase 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in patients with advanced
- 4y agoNGMNGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual MeetingGlobeNewswire--Poster presentation to showcase NGM Bio's in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of
- 4y agoNGMNGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial ResultsGlobeNewswire--Announced that the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration did not meet primary endpoint of statistically significant rate of change in GA
- 4y agoNGMNGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for
- 4y agoNGMNGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationGlobeNewswireTrial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus shamNGM621 showed favorable safety and tolerability, with no evidence
- 4y agoNGMNGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular DegenerationGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT)
- 4y agoNGMNGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic CancerGlobeNewswireNGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 + gemcitabine + Nab-paclitaxel) with
- 4y agoNGMNGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of NGM120 in Patients with Advanced Pancreatic Cancer at the American Association for Cancer Research (AACR) Special Conference: Pancreatic CancerGlobeNewswirePoster presentation at upcoming ESMO Annual Congress to highlight analysis of subgroup of patients with prostate cancer in NGM120 Phase 1a trial Short-talk presentation at upcoming AACR Special Conference: Pancreatic Cancer to highlight analysis of pat
- 4y agoNGMNGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial ResultsGlobeNewswire--Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with advanced solid tumors-- --Initiated the Phase1b port
- 4y agoNGMNGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial OfficerGlobeNewswire-- William J. Rieflin to transition from Executive Chairman to Chairman of the Board of Directors -- SOUTH SAN FRANCISCO, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focu
- 4y agoNGMNGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022GlobeNewswire--NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy, will be showcased in the fourth of a four-part series titled the "Explorer Series"-- SOUTH SAN FRAN
- 4y agoNGMNGM Bio to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Wo
- 4y agoNGMNGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022GlobeNewswire--NGM707, NGM Bio's most advanced myeloid reprogramming antibody product candidate, will be showcased in the third of a four-part series titled the "Explorer Series"-- SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceutic
- 4y agoNGMNGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid TumorsGlobeNewswire--Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA®-- --All three of NGM Bio's wholly-owned myeloid reprogramming product
- 4y agoNGMNGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial ResultsGlobeNewswireInitiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with advanced solid tumors Presented preclinical research f
- 4y agoNGMNGM Bio to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. W
- 4y agoNGMNGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host th
- 4y agoNGMNGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming PortfolioGlobeNewswireILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an immune-suppressive state in the tumor microenvironment NGM707, NGM831 and NGM438 are all engineered to release myeloid checkpoints and reprogram myeloid
- 4y agoNGMStudy of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors - NCT05311618ClinicalTrials.govNumber of Patients with Dose-limiting Toxicities, Number of Patients with Adverse Events, Number of Patients with Clinically Significant Laboratory Abnormalities, (and 12 more...)
- 4y agoNGMNGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid TumorsGlobeNewswireDose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and expected to enroll up to approximately 80 patients
- 4y agoNGMNGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022GlobeNewswire--The four-part series titled the "Explorer Series" will showcase NGM Bio's discovery engine, myeloid reprogramming and checkpoint inhibition portfolio and program for the treatment of geographic atrophy-- SOUTH SAN FRANCISCO, Calif.,
- 4y agoNGMNGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual MeetingGlobeNewswireOral presentation to showcase NGM Bio's in vitro and in vivo research demonstrating potential advantages of dual ILT2/ILT4 inhibition with NGM707, currently in Phase 1/2 trial Late-breaking poster presentations to highlight preclinical research support
- 4y agoNGMNGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireAdvanced programs across NGM Bio's pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022: Obtained Fast Track designation from the U.S. Food and Drug Administration (FDA) for NGM621, an
- 4y agoNGMNGM Bio to Participate in the Cowen 42nd Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Wo
- 4y agoNGMMarathon Health Expands Board of DirectorsPR NewswireINDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ -- Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced pri
- 4y agoNGMNGM Bio's NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular DegenerationGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that the U.S. Fo